These effects were more pronounced when the c-Met inhibitor was combined with a small-molecule FAK inhibitor, suggesting that simultaneous administration of c-Met and FAK inhibitors could constitute a new potential strategy for medulloblastoma therapy 54. The gene discussed is MET; the disease is medulloblastoma.